Kenneth B. Gordon
Impact in
- Immunology top 0.05%
- Psoriasis: Treatment and Pathogenesis
- Dermatology top 0.02%
- Dermatology and Skin Diseases
Papers in
- Immunology 203
- Psoriasis: Treatment and Pathogenesis 195
- Dermatology 46
- Dermatology and Skin Diseases 37
- Co-authors
- Craig L. Leonardi (28 shared papers)Kim Alexander Papp (46 shared papers)Alan Menter (27 shared papers)Mark Lebwohl (37 shared papers)Alice Bendix Gottlieb (29 shared papers)Richard G B Langley (29 shared papers)Alexa B. Kimball (16 shared papers)Neil J. Korman (17 shared papers)
- Journals
- Journal of the American Academy of Dermatology (58 papers)British Journal of Dermatology (14 papers)Journal of the European Academy of Dermatology and Venereology (13 papers)Seminars in Cutaneous Medicine and Surgery (12 papers)Journal of Dermatological Treatment (10 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Kenneth B. Gordon
221 papers receiving 20.5k citations
Kenneth B. Gordon's Hit Papers
Peers
Comparison fields: 5 of 147
- Immunology 16.3k
- Dermatology 5.9k
- Rheumatology 3.1k
- Hematology 1.6k
- Pathology and Forensic Medicine 2.2k
Countries citing papers authored by Kenneth B. Gordon
This map shows the geographic impact of Kenneth B. Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth B. Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth B. Gordon more than expected).
Fields of papers citing papers by Kenneth B. Gordon
This network shows the impact of papers produced by Kenneth B. Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth B. Gordon. The network helps show where Kenneth B. Gordon may publish in the future.
Co-authors
The 25 scholars most cited alongside Kenneth B. Gordon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 235 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Hit paper breakdown → | 2008 | 1599 |
| 2 | Guidelines of care for the management of psoriasis and psoriatic arthritis Hit paper breakdown → | 2008 | 1040 |
| 3 | 2007 | 755 | |
| 4 | Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Hit paper breakdown → | 2016 | 729 |
| 5 | Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis Hit paper breakdown → | 2015 | 709 |
| 6 | Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics Hit paper breakdown → | 2019 | 703 |
| 7 | Guidelines of care for the management of psoriasis and psoriatic arthritis Hit paper breakdown → | 2008 | 661 |
| 8 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial Hit paper breakdown → | 2017 | 605 |
| 9 | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Hit paper breakdown → | 2015 | 555 |
| 10 | Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Hit paper breakdown → | 2018 | 535 |
| 11 | Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease Hit paper breakdown → | 2012 | 472 |
| 12 | 2009 | 464 | |
| 13 | 2006 | 445 | |
| 14 | 2011 | 395 | |
| 15 | 2009 | 389 | |
| 16 | Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities Hit paper breakdown → | 2019 | 376 |
| 17 | 2008 | 371 | |
| 18 | 2013 | 350 | |
| 19 | 2003 | 339 | |
| 20 | 2018 | 332 |
About Kenneth B. Gordon
Kenneth B. Gordon is a scholar working on Immunology, Dermatology, Pathology and Forensic Medicine, Rheumatology and Hematology, having authored 235 papers that have together received 21.3k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (195 papers), Dermatology and Skin Diseases (37 papers), Autoimmune Bullous Skin Diseases (26 papers), Health Systems, Economic Evaluations, Quality of Life (23 papers), Pharmaceutical studies and practices (17 papers), Asthma and respiratory diseases (16 papers), Autoimmune and Inflammatory Disorders Research (12 papers) and Spondyloarthritis Studies and Treatments (11 papers). The work is most often cited by research in Immunology (16.3k citations), Dermatology (5.9k citations), Rheumatology (3.1k citations), Hematology (1.6k citations) and Pathology and Forensic Medicine (2.2k citations). Kenneth B. Gordon has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Craig L. Leonardi, Kim Alexander Papp, Alan Menter, Mark Lebwohl, Alice Bendix Gottlieb, Richard G B Langley, Alexa B. Kimball, Neil J. Korman, Steven R. Feldman and Kristian Reich. Their work appears in journals such as Journal of the American Academy of Dermatology, British Journal of Dermatology, Journal of the European Academy of Dermatology and Venereology, Seminars in Cutaneous Medicine and Surgery and Journal of Dermatological Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.